Abstract:The gut bacterial community is involved in the metabolism of bile acids and short-chain fatty acids (SCFAs). Bile acids are involved in the absorption of fat and the regulation of lipid homeostasis through emulsification and are transformed into unconjugated bile acids by the gut microbiota. The gut microbiota is actively involved in the production of bile acid metabolites, such as deoxycholic acid, lithocholic acid, choline, and SCFAs such as acetate, butyrate, and propionate. Metabolites derived from the gut microbiota or modified gut microbiota metabolites contribute significantly to host pathophysiology. Gut bacterial metabolites, such as deoxycholic acid, contribute to the development of hepatocellular carcinoma and colon cancer by factors such as inflammation and oxidative DNA damage. Butyrate, which is derived from gut bacteria such as Megasphaera, Roseburia, Faecalibacterium, and Clostridium, is associated with the activation of Treg cell differentiation in the intestine through histone acetylation. Butyrate averts the action of class I histone deacetylases (HDAC), such as HDAC1 and HDAC3, which are responsible for the transcription of genes such as p21/Cip1, and cyclin D3 through hyperacetylation of histones, which orchestrates G1 cell cycle arrest. It is essential to identify the interaction between the gut microbiota and bile acid and SCFA metabolism to understand their role in gastrointestinal carcinogenesis including colon, gastric, and liver cancer. Metagenomic approaches with bioinformatic analyses are used to identify the bacterial species in the metabolism of bile acids and SCFAs. This review provides an overview of the current knowledge of gut microbiota-derived bile acid metabolism in tumor development and whether it can stand as a marker for carcinogenesis. Additionally, this review assesses the evidence of gut microbiota-derived short-chain fatty acids including butyric acid in antitumor activity. Future research is required to identify the beneficial commensal gut bacteria and their metabolites which will be considered to be therapeutic targets in inflammation-mediated gastrointestinal cancers.

Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis

Bile Acids and Microbiota: Multifaceted and Versatile Regulators of the Liver–Gut Axis

Intestinal Crosstalk Between Microbiota and Serotonin and Its Impact on Gut Motility

The influence of bile acid, microbiota and their interaction on inflammatory bowel disease and the related progress in clinical application

The gut microbiota at the intersection of bile acids and intestinal carcinogenesis: An old story, yet mesmerizing

The gut microbiome-bile acid axis in hepatocarcinogenesis

Role of bile acids in liver diseases mediated by the gut microbiome

Interplay between bile acids and the gut microbiota promotes intestinal carcinogenesis

Bile's Hidden Weapon: Modulating the Microbiome and Tumor Microenvironment

Crosstalk between bile acid-activated receptors and microbiome in entero-hepatic inflammation

Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma

Bile Acids and Microbiota Interplay in Pancreatic Cancer

Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma

Interplay between Dysbiosis of Gut Microbiome, Lipid Metabolism, and Tumorigenesis: Can Gut Dysbiosis Stand as a Prognostic Marker in Cancer?

Bile Acid–Gut Microbiota Axis in Inflammatory Bowel Disease: From Bench to Bedside

Interactive Relationships Between Intestinal Flora and Bile Acids.

Bile Acid–Microbiome Interaction Promotes Gastric Carcinogenesis

Bile acid metabolism and signaling, the microbiota, and metabolic disease

Crosstalk between Gut Microbiota and Bile Acids in Cholestatic Liver Disease

Bile acids and their receptors in regulation of gut health and diseases

Secondary Bile Acids and Tumorigenesis in Colorectal Cancer